No price history available.

Not enough data to calculate KvantraRank

Based on consensus from external analysts. Not Kvantra's opinion.

Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.

• Vor Biopharma Inc.
• Everest Medicines Limited
• Star Lake Bioscience Co., Inc.Zhaoqing Guangdong
• HBM Holdings Limited
• MannKind Corporation
• MeiraGTx Holdings plc
• Aktis Oncology, Inc.
• Wave Life Sciences Ltd.